Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

2019822 citationsJournal Articlebronze Open Access

Authors

Dennis J. Slamon · University of California, Los Angeles

Patrick Neven · Breast Center

Stephen Chia · BC Cancer Agency

Peter A. Fasching · Universitätsklinikum Erlangen

Michelino De Laurentiis · Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Seock‐Ah Im · Seoul National University Hospital

Katarína Petráková

Abstract

Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor-positive, HER2-negative advanced breast cancer. (Funded by Novartis; MONALEESA-3 ClinicalTrials.gov number, NCT02422615.).

Topics & Keywords

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 6, pp. 514-524

DOI: 10.1056/nejmoa1911149

Field-Weighted Citation Impact: 70.08